We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...
More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.
Biogen said the U.S. Food and Drug Administration has accepted its supplemental new-drug application, while the European Medicines Agency has validated its application, which confirms that the ...
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...
During the COVID-19 pandemic, when fentanyl overdoses surged, doctors were desperate to find ways of helping their patients.